Form 4: ANI Pharmaceuticals CEO Nikhil Lalwani Reports Share Disposal for Tax Obligations
SEC Form 4 Filing
Nikhil Lalwani, CEO of ANI Pharmaceuticals, disposed of shares to cover tax obligations related to the vesting of restricted stock.
Summary
- On March 23, 2025, Nikhil Lalwani, the President & CEO of ANI Pharmaceuticals, disposed of 17,455 shares of common stock.
- The shares were disposed of at a price of $64.26 per share.
- This transaction was to cover tax obligations related to the vesting of 34,124 shares of restricted stock.
- Following the transaction, Lalwani beneficially owns 468,179 shares of ANI Pharmaceuticals.
- The transaction was exempt under Rule 16(b)-3.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock transactions for tax purposes, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the change in beneficial ownership, but it is a routine transaction.
Key Dates
| Date | Description |
|---|---|
| 03/23/2025 | Date of the transaction where shares were disposed of. |
| 03/25/2025 | Date of signature for the Form 4 filing. |
Keywords
ANI Pharmaceuticals, Nikhil Lalwani, Form 4, Share Disposal, Beneficial Ownership, Tax Obligations, Restricted Stock, ANIP
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.